Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Postoperative Pain, Bunion
Interventions: CPL-01, saline placebo; Drug
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Irritable Bowel Syndrome, Dyspepsia, Functional Bloating
Interventions: Biofeedback, Placebo; Behavioral
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small-Cell Lung
Interventions: Canakinumab, Docetaxel, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more

Conditions: Healthy
Interventions: PF-04634817 Placebo, PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions: Dapansutrile, Placebo Tablet; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Acute Heart Failure
Interventions: Placebo, Nesiritide, Dopamine; Other · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more

Conditions: Urinary Tract Infection
Interventions: Lactin-V, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson's Disease
Interventions: Ampyra first, then Placebo, placebo first, then Ampyra; Drug
Lead sponsor: University of Miami; Other
Eligibility: 45 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alopecia Areata
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Depression, Major Depressive Disorder, Unipolar Depression
Interventions: Wellbutrin, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions: SLN360, Placebo; Drug
Lead sponsor: Silence Therapeutics plc; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Autistic Disorder
Interventions: Aripiprazole, Placebo, D-cycloserine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pediatric Traumatic Brain Injury
Interventions: Probenecid and N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 2 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chagas Disease
Interventions: Benznidazole, Placebo Oral Tablet; Drug
Lead sponsor: Tulane University School of Public Health and Tropical Medicine; Other
Eligibility: 13 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Diego, California • New Orleans, Louisiana

Conditions: Healthy
Interventions: Placebo Administration first, Low Caffeine Administration first (1mg/kg body weight), High Caffeine Administration first (2mg/kg body weight); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 8 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Heart Disease
Interventions: APL180, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Anniston, Alabama • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Opioid Abuse, Opioid Dependence
Interventions: MN-166 (50 mg) First, Placebo First; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Abdominal Pain, Surgical Adhesions
Interventions: Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks, Placebo first followed by open label pregabalin; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Raynaud's Disease, Peripheral Vascular Disease
Interventions: PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions: Placebo, Memantine Hydrochloride, OROS-Methylphenidate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 50
States / cities: Fairhope, Alabama • Beverly Hills, California • Los Angeles, California + 41 more

Search by objective public record fields.

Phase 3 Bunionectomy Study

Visible Abdominal Distension

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

First In Human Study Of Increasing Oral Doses Of PF-04634817

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

Gender Difference in Response to Caffeine in Children and Adolescents

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

Pregabalin for Abdominal Pain From Adhesions

PF-00489791 For The Treatment Of Raynaud's

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity